IX1 Stock Financial Analysis - IDEXX Laboratories, Inc. (XTRA) Stock

Overview

IDEXX Laboratories, Inc., based in the United States, operates primarily within the veterinary diagnostics sector, along with providing associated veterinary software and services. Renowned for innovation in the development of advanced veterinary diagnostic and IT solutions, IDEXX's portfolio significantly enhances the health and well-being of pets, livestock, and poultry worldwide. Key projects focus on the enhancement of diagnostic technologies such as the Catalyst Dx chemistry analyzer and the SediVue Dx Urine Sediment Analyzer, which bolster the efficiency and range of in-clinic diagnostic capabilities. Additionally, IDEXX's Water division contributes globally to water quality testing, supporting public health and safety.

Quality, Value, Momentum Scores

This card shows the Quality, Value, and Momentum scores for the company

Quality

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Value

Proprietary scoring model that ranks companies based on their relative valuation. Scores range from 0 to 100, with 100 being the most undervalued.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Fund Sentiment

The Fund Sentiment (fka Ownership) score is a proprietary quantitative model that ranks companies based on levels of ownership accumulation.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Income Statement: Revenue, Operating Income, Net Income

The revenue for IDEXX Laboratories, Inc. as of 30 June 2025 is 4,037.72 MM.
The operating income for IDEXX Laboratories, Inc. as of 30 June 2025 is 1,255.16 MM.
The net income for IDEXX Laboratories, Inc. as of 30 June 2025 is 985.66 MM.

Period End (TTM)	Revenue (MM)	Operating Income (MM)	Net Income (MM)
2025-06-30	4,037.72	1,255.16	985.66
2025-03-31	3,931.84	1,207.41	894.97
2024-12-31	3,897.50	1,189.84	887.87
2024-09-30	3,844.82	1,173.45	866.24
2024-06-30	3,784.80	1,144.84	845.63
2024-03-31	3,724.85	1,115.69	866.57
2023-12-31	3,660.95	1,097.13	845.04
2023-09-30	3,587.92	1,078.35	822.73
2023-06-30	3,514.05	1,047.90	791.43
2023-03-31	3,430.97	930.82	699.18
2022-12-31	3,367.32	898.76	679.09
2022-09-30	3,339.85	871.43	669.65
2022-06-30	3,308.61	852.56	663.95
2022-03-31	3,274.20	932.75	734.55
2021-12-31	3,215.36	932.03	744.85
2021-09-30	3,135.21	917.93	756.86
2021-06-30	3,046.58	863.83	727.85
2021-03-31	2,858.03	797.82	674.21
2020-12-31	2,706.66	694.52	581.78
2020-09-30	2,591.16	638.46	497.48
2020-06-30
2020-03-31

Income Statement: EPS

Period End (TTM)	Earnings Per Share Basic	Earnings Per Share Diluted
2025-06-30
2025-03-31
2024-12-31	10.77	10.67
2024-09-30	10.46	10.36
2024-06-30	10.19	10.08
2024-03-31	10.43	10.32
2023-12-31	10.17	10.06
2023-09-30	9.91	9.81
2023-06-30	9.53	9.43
2023-03-31	8.40	8.30
2022-12-31	8.12	8.03
2022-09-30	7.96	7.86
2022-06-30	7.85	7.73
2022-03-31	8.65	8.52
2021-12-31	8.74	8.60
2021-09-30	8.87	8.72
2021-06-30	8.52	8.39
2021-03-31	7.90	7.77
2020-12-31	6.82	6.71
2020-09-30	5.82	5.74
2020-06-30	5.37	5.29
2020-03-31	5.08	5.01

Cash Flow: Operations, Investing, Financing

The cash from operating activities for IDEXX Laboratories, Inc. as of 30 June 2025 is 905.81 MM.
The cash from investing activities for IDEXX Laboratories, Inc. as of 30 June 2025 is -130.45 MM.
The cash from financing activities for IDEXX Laboratories, Inc. as of 30 June 2025 is -1,019.71 MM.

Period End (TTM)	Cash From Operating Activities (MM)	Cash From Investing Activities (MM)	Cash From Financing Activities (MM)
2025-06-30	905.81	-130.45	-1,019.71
2025-03-31	968.38	-129.73	-1,064.32
2024-12-31	929.00	-207.06	-878.07
2024-09-30	916.83	-197.65	-747.13
2024-06-30	969.18	-198.12	-499.19
2024-03-31	921.18	-192.69	-439.99
2023-12-31	906.51	-125.25	-442.00
2023-09-30	830.09	-144.05	-456.87
2023-06-30	746.65	-165.41	-562.66
2023-03-31	612.19	-193.02	-503.54
2022-12-31	542.98	-195.35	-370.94
2022-09-30	579.52	-190.16	-420.04
2022-06-30	577.73	-190.64	-492.93
2022-03-31	745.83	-310.22	-581.24
2021-12-31	755.55	-292.97	-697.41
2021-09-30	764.52	-264.62	-531.20
2021-06-30	770.43	-234.40	-413.65
2021-03-31	744.61	-84.29	-394.97
2020-12-31	648.06	-109.38	-248.42
2020-09-30	584.54	-189.60	-323.20
2020-06-30
2020-03-31

Valuation Metrics : PE, PriceToBook, PriceToTBV

P/Book: The current closing price divided by the book value per share.

P/TBV: The current price divided by the tangible book value per share.

Period End (TTM)	p/e	P/Book	P/TBV
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31

Valuation Metrics : EBitToEv, EBit3YrAvgToEv

Period End (TTM)	EBIT/EV	EBIT (3y)/EV
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31

Management Effectiveness

The roa for IDEXX Laboratories, Inc. as of 30 June 2025 is 0.26.
The roe for IDEXX Laboratories, Inc. as of 30 June 2025 is 0.57.
The roic for IDEXX Laboratories, Inc. as of 30 June 2025 is 0.36.
The croic for IDEXX Laboratories, Inc. as of 30 June 2025 is -0.09.
The ocroic for IDEXX Laboratories, Inc. as of 30 June 2025 is 0.39.

Period End (TTM)	ROA	ROE	ROIC	CROIC	OCROIC
2025-06-30	0.26	0.57	0.36	-0.09	0.39
2025-03-31	0.26	0.57	0.34	-0.06	0.36
2024-12-31	0.27	0.60	0.33	-0.01	0.35
2024-09-30	0.27	0.67	0.32	0.10	0.37
2024-06-30	0.31	1.03	0.33	0.11	0.35
2024-03-31	0.31	1.39	0.33	0.13	0.36
2023-12-31	0.31	1.73	0.34	0.10	0.34
2023-09-30	0.30	1.73	0.35	0.01	0.33
2023-06-30	0.27	1.73	0.33	0.01	0.31
2023-03-31	0.26	1.09	0.30	-0.04	0.27
2022-12-31	0.28	0.89	0.34	-0.02	0.29
2022-09-30	0.28	0.89	0.34	-0.02	0.29
2022-06-30	0.30	0.89	0.36	-0.06	0.32
2022-03-31	0.32	1.04	0.44	-0.09	0.45
2021-12-31	0.33	1.18	0.45	-0.15	0.44
2021-09-30	0.37	1.72	0.43	-0.02	0.44
2021-06-30	0.37	2.66	0.44	0.08	0.47
2021-03-31	0.36	6.24	0.40	0.16	0.44
2020-12-31	0.32	3.27	0.36	0.18	0.40
2020-09-30	0.28	2.45	0.35	0.05	0.41
2020-06-30	0.27	2.68	0.37	-0.00	0.42
2020-03-31	0.26	8.42	0.32	-0.03	0.33

Gross Margins

The gross margin for IDEXX Laboratories, Inc. as of 30 June 2025 is 0.61.
The net margin for IDEXX Laboratories, Inc. as of 30 June 2025 is 0.23.
The operating margin for IDEXX Laboratories, Inc. as of 30 June 2025 is 0.31.

Gross Margin: The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.

Net Margin: The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.

Operating Margin: The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.

Period End (TTM)	Gross Margin	Net Margin	Operating Margin
2025-06-30	0.61	0.23	0.31
2025-03-31	0.61	0.23	0.29
2024-12-31	0.61	0.23	0.31
2024-09-30	0.60	0.22	0.30
2024-06-30	0.60	0.23	0.30
2024-03-31	0.60	0.23	0.30
2023-12-31	0.60	0.23	0.30
2023-09-30	0.60	0.23	0.30
2023-06-30	0.60	0.23	0.30
2023-03-31	0.60	0.20	0.27
2022-12-31	0.59	0.20	0.26
2022-09-30	0.59	0.20	0.26
2022-06-30	0.59	0.20	0.26
2022-03-31	0.59	0.22	0.28
2021-12-31	0.59	0.23	0.29
2021-09-30	0.59	0.24	0.29
2021-06-30	0.59	0.24	0.28
2021-03-31	0.59	0.24	0.28
2020-12-31	0.58	0.21	0.26
2020-09-30	0.58	0.19	0.25
2020-06-30	0.57	0.19	0.25
2020-03-31	0.57	0.18	0.23

IT:1IDXX	554,60 €
MX:IDXX
GB:0J8P	645,30 US$
US:IDXX	642,99 US$
AT:IDXX